{
    "ticker": "HEPA",
    "name": "Hepion Pharmaceuticals, Inc.",
    "description": "Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of chronic liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Founded in 2016, Hepion aims to address significant unmet medical needs in liver health through its proprietary drug candidates, including CRV431, a novel therapeutic agent designed to modulate liver inflammation and fibrosis. The company employs a unique approach that combines advanced drug development methods with a deep understanding of liver biology. Hepion's research is supported by strong preclinical and clinical data, showcasing the potential of its therapies to improve liver function and patient outcomes. With a dedicated team of scientists and industry experts, Hepion is committed to advancing its pipeline and bringing effective treatments to market. The company is also focused on establishing partnerships and collaborations to leverage synergies in the biopharmaceutical sector, enhancing its ability to innovate and expand its reach in the global market. Hepion's mission is to improve the lives of patients suffering from liver diseases through groundbreaking research and development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cranford, New Jersey, USA",
    "founded": "2016",
    "website": "https://www.hepionpharma.com",
    "ceo": "Dr. John C. McNulty",
    "social_media": {
        "twitter": "https://twitter.com/hepionpharma",
        "linkedin": "https://www.linkedin.com/company/hepion-pharmaceuticals"
    },
    "investor_relations": "https://www.hepionpharma.com/investors",
    "key_executives": [
        {
            "name": "Dr. John C. McNulty",
            "position": "CEO"
        },
        {
            "name": "Robert Foster",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CRV431"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hepion Pharmaceuticals, Inc. | Innovating Liver Disease Therapies",
        "meta_description": "Hepion Pharmaceuticals, Inc. is dedicated to developing innovative treatments for chronic liver diseases. Learn about our groundbreaking research and drug candidates.",
        "keywords": [
            "Hepion Pharmaceuticals",
            "CRV431",
            "Liver Disease",
            "NASH",
            "NAFLD",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does Hepion Pharmaceuticals focus on?",
            "answer": "Hepion Pharmaceuticals focuses on developing therapies for chronic liver diseases, particularly NASH and NAFLD."
        },
        {
            "question": "Who is the CEO of Hepion Pharmaceuticals?",
            "answer": "Dr. John C. McNulty is the CEO of Hepion Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Hepion headquartered?",
            "answer": "Hepion is headquartered in Cranford, New Jersey, USA."
        },
        {
            "question": "What is Hepion's main product?",
            "answer": "Hepion's main product is CRV431, a novel therapeutic for liver diseases."
        },
        {
            "question": "When was Hepion Pharmaceuticals founded?",
            "answer": "Hepion Pharmaceuticals was founded in 2016."
        }
    ],
    "competitors": [
        "VRTX",
        "GILD",
        "MRNA",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "PFE",
        "JNJ"
    ]
}